Investors searching for Revance Therapeutics stock today will find a chapter closed. The company ceased to exist as an independent, publicly traded entity following its acquisition by Crown Laboratories, which was finalized approximately one year ago. This move signals a significant consolidation within the competitive aesthetics industry.
A Strategic Acquisition and Brand Consolidation
The takeover by Crown Laboratories was completed in February 2025, resulting in the delisting of Revance shares from the NASDAQ Global Select Market. In a subsequent strategic decision made in March 2025, the combined corporate entity chose to operate entirely under the Revance brand name. This leverages the established market recognition of Revance to promote a unified portfolio that merges skincare with medical aesthetics, aiming to create a more powerful competitor in a dynamic sector.
Should investors sell immediately? Or is it worth buying Revance Therapeutics?
Sector Trend: Private Consolidation of Biotech Innovation
This transaction exemplifies a broader industry pattern where larger, often private, companies absorb innovative firms with specialized product offerings. The goal is to unlock synergies, particularly in the expanding realm of lifestyle-oriented healthcare. Revance contributed key strategic assets to this union, including the neuromodulator DAXXIFY and the RHA Filler collection. These products complement Crown Laboratories’ existing skincare lines, enabling the new organization to position itself as a comprehensive provider for aesthetic treatments.
Final Settlement for Former Shareholders
For former equity holders of Revance Therapeutics, the investment was conclusively settled as part of the acquisition process. All shares were converted into cash payments according to the terms of the merger agreement. With the cessation of public trading, there is no longer a liquid market for the stock. Former shareholders requiring details regarding their payout must contact the transfer agent specified in the original takeover documents.
Ad
Revance Therapeutics Stock: Buy or Sell?! New Revance Therapeutics Analysis from February 8 delivers the answer:
The latest Revance Therapeutics figures speak for themselves: Urgent action needed for Revance Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.
Revance Therapeutics: Buy or sell? Read more here...
